

22(new). A polynucleotide sequence encoding a polypeptide comprising a humanized antibody as defined in claim 21, said antibody comprising at least one of the following sequence:

a heavy chain variable region sequence which is VH1 (SEQ ID NO:55);

a light chain variable region sequence which is VK4 (SEQ ID NO:71);

a human CH1 heavy chain IgG3 constant region;

a human kappa light chain CL region; and

a human IgG3 hinge region;

optionally in the form of a f(ab')₂ fragment.

REMARKS

This application is filed as a divisional of USSN 09/171,945. This amendment includes claims cancelled in the parent application. No new matter has been added with this amendment.

RESPECTFULLY SUBMITTED,					
NAME AND REG. NUMBER	Barbara G. Ernst, Reg. No. 30,377				
SIGNATURE	Barbara G. Ernst		DATE	July 23, 2001	
Address	Rothwell, Figg, Ernst & Manbeck Suite 701-East, 555 13th Street, N.W.				
City	Washington	State	D.C.	Zip Code	20004
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031

Attachments: Marked-Up Copies of Amendments

Amend d Claims: Version with markings to show changes made

8. A polynucleotide sequence ~~capable of encoding a polypeptide of~~ comprising an anti-CEA antibody ("806.077-Ab") or a conjugate as defined in any preceding claim comprising complementarity determining regions (CDRs) in which the CDRs comprise the following sequences:

a) heavy chain

CDR1: DNYMH (SEQ ID NO: 29)

CDR2: WIDRENGDTIEYAPKFRG (SEQ ID NO: 31)

CDR3: LIYAGYLAMDY (SEQ ID NO: 32); and

b) light chain

CDR1: SASSSVIYMH (SEQ ID NO: 26)

CDR2: STSNLAS (SEQ ID NO: 27)

CDR3: QQRSTYPLT (SEQ ID NO: 28)

9. A vector comprising a polynucleotide as defined in claim 8, 20, 21 or 22.

14. A method of making an antibody ~~or conjugate~~ as defined in ~~any preceding claim~~ 8 which comprises:

a) ~~subjecting a host cell, a transgenic non-human mammal or a transgenic plant as defined in claim 10, or the hybridoma of claim 11, to conditions conducive to expression, and optionally secretion, of the antibody or conjugate; and optionally~~

~~— b) at least partially purifying the antibody or conjugate.~~